KRAS Patient Case

Ramya Muddasani, DO, MS, leads a discussion on the treatment of a patient with metastatic NSCLC with a KRAS G12C mutation, highlighting the utilization of sotorasib and the CodeBreaK 100 trial.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Introduction of the UCSD vs City of Hope Face-Off

EP: 2.Advanced ALK-Rearranged NSCLC

EP: 3.Lorlatinib vs Crizotinib in Treatment-naïve Advanced ALK+ NSCLC: 5-year PFS and Safety from CROWN

EP: 4.CheckMate-9LA: 5-Year Update with Nivolumab + Ipilimumab + Chemotherapy in mNSCLC

EP: 5.Where Does the POSEIDON Regimen Fit in the NSCLC Treatment Landscape?

EP: 6.A Case of Metastatic ROS1 Fusion-Positive NSCLC

EP: 7.Patient Profile: EGFRm Post-Osimertinib

EP: 8.Patient Case: PD-L1 Negative NSCLC

Now Viewing

EP: 9.KRAS Patient Case

EP: 10.Neoadjuvant Chemoimmunotherapy for Resectable NSCLC

EP: 11.Will Neoadjuvant Therapies Replace Surgery Plus Adjuvant Treatment for Resectable NSCLC?

EP: 12.Treatment Options for Patients with EGFRm: EGFR TKI + Chemotherapy

EP: 13.Treatment Options for Patients with EGFRm: EGFR TKI

EP: 14.Face-Off: Award Ceremony

Recent Videos

Clinical Scenario: TP53- Mutant AML

Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation

Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center

Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma

Clinical Scenario: A 58-Year Old Woman with Relapsed Refractory Mutiple Myeloma, post-ASCT, MRD-negative, on Bispecific Therapy

Dosing Interval and Considerations for Bispecifics Combination in Relapsed Refractory Multiple Myeloma